Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy

Executive Summary

Agency reinterprets definition of "first applicant" and applies "failure to market" forfeiture provision of MMA; court halts sales of Dr. Reddy's generic.

You may also be interested in...



Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.

Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000

Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB002474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel